Compania, Sabturane L.
HRN: 25-41-25 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/01/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
07/01/2024
07/08/2024
IVT
600mg
Q6h
Fracture
Waiting Final Action
Indication: Empiric Type of Infection: Bone & Joint Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes